BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jing X, Liang H, Hao C, Yang X, Cui X. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncol Rep 2019;41:801-10. [PMID: 30483806 DOI: 10.3892/or.2018.6887] [Cited by in Crossref: 23] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Alkhatib H, Rubinstein AM, Vasudevan S, Flashner-Abramson E, Stefansky S, Chowdhury SR, Oguche S, Peretz-Yablonsky T, Granit A, Granot Z, Ben-Porath I, Sheva K, Feldman J, Cohen NE, Meirovitz A, Kravchenko-Balasha N. Computational quantification and characterization of independently evolving cellular subpopulations within tumors is critical to inhibit anti-cancer therapy resistance. Genome Med 2022;14:120. [PMID: 36266692 DOI: 10.1186/s13073-022-01121-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chen L, Chen F, Niu H, Li J, Pu Y, Yang C, Wang Y, Huang R, Li K, Lei Y, Huang Y. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities. Front Immunol 2022;13:871661. [DOI: 10.3389/fimmu.2022.871661] [Reference Citation Analysis]
3 Khandakar H, Agarwal S, Sharma MC, Kandasamy D, Bal C, Rathode Y, Aphale R. Amphicrine Medullary Thyroid Carcinoma - a Case-Based Review Expanding on Its MUC Expression Profile. Endocr Pathol 2022. [PMID: 35733030 DOI: 10.1007/s12022-022-09725-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Marino N, German R, Podicheti R, Rusch DB, Rockey P, Huang J, Sandusky GE, Temm CJ, Althouse S, Nephew KP, Nakshatri H, Liu J, Vode A, Cao S, Storniolo AMV. Aberrant epigenetic and transcriptional events associated with breast cancer risk. Clin Epigenetics 2022;14:21. [PMID: 35139887 DOI: 10.1186/s13148-022-01239-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Vafaei R, Samadi M, Hosseinzadeh A, Barzaman K, Esmailinejad M, Khaki Z, Farahmand L. Comparison of mucin-1 in human breast cancer and canine mammary gland tumor: a review study. Cancer Cell Int 2022;22:14. [PMID: 35000604 DOI: 10.1186/s12935-021-02398-6] [Reference Citation Analysis]
6 Maurya RK, Tripathi AS, Mohapatra L, Soni S, Yasir M. Relationship of Breast Cancer with Other Hormone-Sensitive Cancers. Breast Cancer: From Bench to Personalized Medicine 2022. [DOI: 10.1007/978-981-19-0197-3_3] [Reference Citation Analysis]
7 Song F, Chen FY, Wu SY, Hu B, Liang XL, Yang HQ, Cheng JW, Wang PX, Guo W, Zhou J, Fan J, Chen Z, Yang XR. Mucin 1 promotes tumor progression through activating WNT/β-catenin signaling pathway in intrahepatic cholangiocarcinoma. J Cancer 2021;12:6937-47. [PMID: 34729096 DOI: 10.7150/jca.63235] [Reference Citation Analysis]
8 Qiang Z, Zhang H, Jin S, Yan C, Li Z, Tao L, Yu H. The prognostic value of arginase-1 and glypican-3 expression levels in patients after surgical intrahepatic cholangiocarcinoma resection. World J Surg Oncol 2021;19:316. [PMID: 34715880 DOI: 10.1186/s12957-021-02426-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Jarahian M, Marofi F, Maashi MS, Ghaebi M, Khezri A, Berger MR. Re-Expression of Poly/Oligo-Sialylated Adhesion Molecules on the Surface of Tumor Cells Disrupts Their Interaction with Immune-Effector Cells and Contributes to Pathophysiological Immune Escape. Cancers (Basel) 2021;13:5203. [PMID: 34680351 DOI: 10.3390/cancers13205203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Zhang Z, Liu X, Li L, Yang Y, Yang J, Wang Y, Wu J, Wu X, Shan L, Pei F, Liu J, Wang S, Li W, Sun L, Liang J, Shang Y. SNP rs4971059 predisposes to breast carcinogenesis and chemoresistance via TRIM46-mediated HDAC1 degradation. EMBO J 2021;40:e107974. [PMID: 34459501 DOI: 10.15252/embj.2021107974] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Varty K, O'Brien C, Ignaszak A. Breast Cancer Aptamers: Current Sensing Targets, Available Aptamers, and Their Evaluation for Clinical Use in Diagnostics. Cancers (Basel) 2021;13:3984. [PMID: 34439139 DOI: 10.3390/cancers13163984] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Striefler JK, Riess H, Lohneis P, Bischoff S, Kurreck A, Modest DP, Bahra M, Oettle H, Sinn M, Bläker H, Denkert C, Stintzing S, Sinn BV, Pelzer U. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Front Oncol 2021;11:670396. [PMID: 34386419 DOI: 10.3389/fonc.2021.670396] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Li N, Zeng Y, Tai M, Lin B, Zhu D, Luo Y, Ren X, Zhu X, Li L, Wu H, Huang J. Analysis of the Prognostic Value and Gene Expression Mechanism of SHOX2 in Lung Adenocarcinoma. Front Mol Biosci 2021;8:688274. [PMID: 34262939 DOI: 10.3389/fmolb.2021.688274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Parks RM, Alfarsi LH, Green AR, Cheung KL. Biology of primary breast cancer in older women beyond routine biomarkers. Breast Cancer 2021;28:991-1001. [PMID: 34165702 DOI: 10.1007/s12282-021-01266-5] [Reference Citation Analysis]
15 Kufe DW. MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment. Carcinogenesis 2020;41:1173-83. [PMID: 32710608 DOI: 10.1093/carcin/bgaa082] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 19.0] [Reference Citation Analysis]
16 Ulucan-karnak F, Akgöl S. A New Nanomaterial Based Biosensor for MUC1 Biomarker Detection in Early Diagnosis, Tumor Progression and Treatment of Cancer. Nanomanufacturing 2021;1:14-38. [DOI: 10.3390/nanomanufacturing1010003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zhang C, Yang Z, Zhou P, Yu M, Li B, Liu Y, Jin J, Liu W, Jing H, Du J, Tian J, Zhao Z, Wang J, Chu Y, Zhang C, Novakovic VA, Shi J, Wu C. Phosphatidylserine-exposing tumor-derived microparticles exacerbate coagulation and cancer cell transendothelial migration in triple-negative breast cancer. Theranostics 2021;11:6445-60. [PMID: 33995667 DOI: 10.7150/thno.53637] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
18 Budzik MP, Fudalej MM, Badowska-Kozakiewicz AM. Histopathological analysis of mucinous breast cancer subtypes and comparison with invasive carcinoma of no special type. Sci Rep 2021;11:5770. [PMID: 33707745 DOI: 10.1038/s41598-021-85309-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
19 Sivaganesh V, Promi N, Maher S, Peethambaran B. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer. Int J Mol Sci 2021;22:2433. [PMID: 33670942 DOI: 10.3390/ijms22052433] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
20 Wang N, Chen Y, Shi C, Lin Z, Xie H. CREB3L4 promotes angiogenesis and tumor progression in gastric cancer through regulating VEGFA expression. Cancer Gene Ther 2021. [PMID: 33637885 DOI: 10.1038/s41417-021-00305-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Wright RHG, Beato M. Role of the NUDT Enzymes in Breast Cancer. Int J Mol Sci 2021;22:2267. [PMID: 33668737 DOI: 10.3390/ijms22052267] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
22 Malli IA. From Inflammation to Cancer: Role of Genetic Polymorphisms of Inflammatory Pathway Molecules in Gastric Cancer. Genetic Polymorphism and cancer susceptibility 2021. [DOI: 10.1007/978-981-33-6699-2_4] [Reference Citation Analysis]
23 Jin H. Perspectives of Aptamers for Medical Applications. Aptamers for Medical Applications 2021. [DOI: 10.1007/978-981-33-4838-7_14] [Reference Citation Analysis]
24 Zhao Y, Lin Z, Lin Z, Zhou C, Liu G, Lin J, Zhang D, Lin D. Overexpression of Mucin 1 Suppresses the Therapeutical Efficacy of Disulfiram against Canine Mammary Tumor. Animals (Basel) 2020;11:E37. [PMID: 33375426 DOI: 10.3390/ani11010037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Montaño-Samaniego M, Bravo-Estupiñan DM, Méndez-Guerrero O, Alarcón-Hernández E, Ibáñez-Hernández M. Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters. Front Oncol 2020;10:605380. [PMID: 33381459 DOI: 10.3389/fonc.2020.605380] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 12.5] [Reference Citation Analysis]
26 Parks RM, Albanghali MA, Syed BM, Green AR, Ellis IO, Cheung KL. Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray. Breast Cancer Res Treat 2021;185:647-55. [PMID: 33226492 DOI: 10.1007/s10549-020-06023-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Girotti A, Escalera-Anzola S, Alonso-Sampedro I, González-Valdivieso J, Arias FJ. Aptamer-Functionalized Natural Protein-Based Polymers as Innovative Biomaterials. Pharmaceutics 2020;12:E1115. [PMID: 33228250 DOI: 10.3390/pharmaceutics12111115] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
28 Zhang J, Shi J, Zhang H, Zhu Y, Liu W, Zhang K, Zhang Z. Localized fluorescent imaging of multiple proteins on individual extracellular vesicles using rolling circle amplification for cancer diagnosis. J Extracell Vesicles 2020;10:e12025. [PMID: 33304477 DOI: 10.1002/jev2.12025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
29 Kim S, Seo Y, Chowdhury T, Yu HJ, Lee CE, Kim KM, Kang H, Kim HJ, Park SJ, Kim K, Park CK. Inhibition of MUC1 exerts cell-cycle arrest and telomerase suppression in glioblastoma cells. Sci Rep 2020;10:18238. [PMID: 33106534 DOI: 10.1038/s41598-020-75457-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
30 Tao S, Li H, Ma X, Lian B, He J, Gao Y, Li J. Methylation-Mediated Silencing of MicroRNA-497 Promotes Breast Cancer Progression Through Up-Regulation of Mucin1. Front Oncol 2020;10:552099. [PMID: 33194611 DOI: 10.3389/fonc.2020.552099] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
31 Ciocan-Cȃrtiţă CA, Jurj A, Raduly L, Cojocneanu R, Moldovan A, Pileczki V, Pop LA, Budişan L, Braicu C, Korban SS, Berindan-Neagoe I. New perspectives in triple-negative breast cancer therapy based on treatments with TGFβ1 siRNA and doxorubicin. Mol Cell Biochem 2020;475:285-99. [PMID: 32888160 DOI: 10.1007/s11010-020-03881-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
32 Abdoli Shadbad M, Hajiasgharzadeh K, Baradaran B. Cross-talk between myeloid-derived suppressor cells and Mucin1 in breast cancer vaccination: On the verge of a breakthrough. Life Sci 2020;258:118128. [PMID: 32710947 DOI: 10.1016/j.lfs.2020.118128] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
33 Hong HC, Chuang CH, Huang WC, Weng SL, Chen CH, Chang KH, Liao KW, Huang HD. A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse. Theranostics 2020;10:8771-89. [PMID: 32754277 DOI: 10.7150/thno.46142] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
34 Kim MJ, Choi JR, Tae N, Wi TM, Kim KM, Kim DH, Lee ES. Novel Antibodies Targeting MUC1-C Showed Anti-Metastasis and Growth-Inhibitory Effects on Human Breast Cancer Cells. Int J Mol Sci 2020;21:E3258. [PMID: 32380650 DOI: 10.3390/ijms21093258] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
35 Wang J, Ji H, Niu X, Yin L, Wang Y, Gu Y, Li D, Zhang H, Lu M, Zhang F, Zhang Q. Sodium-Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer. Dis Markers 2020;2020:6103542. [PMID: 32377271 DOI: 10.1155/2020/6103542] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Olou AA, King RJ, Yu F, Singh PK. MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism. Oncogene 2020;39:3381-95. [PMID: 32103170 DOI: 10.1038/s41388-020-1225-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
37 Pu Q, Lu L, Dong K, Geng WW, Lv YR, Gao HD. The Novel Transcription Factor CREB3L4 Contributes to the Progression of Human Breast Carcinoma. J Mammary Gland Biol Neoplasia. 2020;25:37-50. [PMID: 32026099 DOI: 10.1007/s10911-020-09443-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
38 Rashidijahanabad Z, Huang X. Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy. Semin Immunol 2020;47:101390. [PMID: 31982247 DOI: 10.1016/j.smim.2020.101390] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
39 Pickup KE, Pardow F, Carbonell-Caballero J, Lioutas A, Villanueva-Cañas JL, Wright RHG, Beato M. Expression of Oncogenic Drivers in 3D Cell Culture Depends on Nuclear ATP Synthesis by NUDT5. Cancers (Basel) 2019;11:E1337. [PMID: 31510016 DOI: 10.3390/cancers11091337] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
40 Barriga V, Kuol N, Nurgali K, Apostolopoulos V. The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer. Cancers (Basel) 2019;11:E1205. [PMID: 31430935 DOI: 10.3390/cancers11081205] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]